Ministers are facing growing pressure to accelerate access to the weight-loss drug Mounjaro after MPs criticised the current NHS rollout as “unambitious” and warned that only a small fraction of eligible patients are expected to receive treatment in the coming years. The Commons Health and Social Care Committee has called for an urgent review of the programme, arguing that access to obesity treatments is increasingly being determined by an individual’s ability to pay rather than by clinical need. Mounjaro, known medically as tirzepatide, has been widely regarded as one of the most significant advances in obesity treatment in recent years. The medication helps reduce appetite and has delivered substantial weight loss for many patients, offering new hope to those living with obesity and related health conditions. However, despite the potential benefits, access remains tightly controlled.
NHS England estimates that around 2.8 million people could be eligible for Mounjaro under current clinical guidance. If all eligible patients sought treatment immediately, the cost to the health service has been estimated at more than £15 billion over five years. As a result, the rollout has been deliberately phased. Under existing plans, around 220,000 patients are expected to receive access during the first three years, representing approximately 6% of those who may qualify for treatment. MPs argue that such a gradual approach fails to reflect the scale of the obesity crisis facing the country. The committee’s report also highlights concerns about the emergence of a two-tier healthcare system. While demand for weight-loss injections continues to surge, many patients who cannot obtain treatment through the NHS are turning to private providers instead. MPs say obesity should be treated as a long-term health condition, similar to diabetes, requiring ongoing medical support and access to proven treatments. They have urged the Government to work with healthcare professionals, digital providers and NHS leaders to identify ways of expanding access more quickly. The report also raises wider concerns about obesity services across England, arguing that patients often struggle to access behavioural support, specialist weight-management programmes and bariatric services alongside medication. NHS officials maintain that current access is being prioritised for patients with the greatest clinical need while new delivery models are explored to increase availability over time.
Why It Matters to the West Midlands
Obesity remains a major public health challenge across parts of the West Midlands, contributing to higher rates of type 2 diabetes, heart disease and other long-term health conditions. Expanding access to effective treatments could play a significant role in improving health outcomes, reducing pressure on local NHS services and helping more people remain active and independent.
Healthcare leaders, local authorities and patient groups across the region are likely to watch closely as the debate over access to weight-loss medications continues.
What Happens Next?
The committee is urging ministers to reassess the current timetable and develop a more ambitious strategy for delivering obesity treatments through the NHS. With demand continuing to grow and private prescriptions rising rapidly, pressure is increasing on policymakers to decide whether wider access to drugs such as Mounjaro should become a central part of the UK’s long-term approach to tackling obesity.
